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Abstract 
Objectives: To obtain outcomes data on anatomical and 
reverse total shoulder arthroplasty by analysis of clinical 
scores and standard radiographs. 
Subject selection and enrollment: 400 consecutive 
series of patients replaced with anatomical and reverse 
total shoulder arthroplasty (minimum 3 years follow-up). 
Study Design: retrospective monocenter. 
Preoperative assessment: Demographics, clinical scores 
(Constant-Murley) as available, shoulder X-ray (AP, 
outlet and axillary views) . 
Last follow-up: Postoperative radiographhs and clinical 
scores. Adverse events and complications to be reported 
as occurred since implantation. 
Statistical analysis: Data collected will be summarized 
and analyzed for statistical significance. 
I. INTRODUCTION 
Shoulder arthroplasty is an effective device to treat 
osteoarthritis and other degenerative conditions of the 
glenohumeral joint. Modern prosthetic implants allow a 
total replacement of the shoulder joint to gain a pain free  
range of motion, and as result  this leads to a significant 
improvement in patient’s quality of life 1-8. For over 
30 years, orthopedic surgeons used anatomical and 
reverse prosthetic implants that ensured safety and 
reliability.  
Indications for one or the other type of prosthesis 
depends on the quality of the rotator cuff (RC) tendons, 
reserving reverse arthroplasty for those with severe 
insufficiency of the RC 7. In our Shoulder Unit both 
type of prostheses have been implanted to treat shoulder 
osteoarthritis and proximal humeral fractures, but the 
results previous published refer to small sample size and 
short-term follow-up. 
II. PURPOSE 
Aim of the current study will be to assess clinical and 
radiological outcomes of anatomical and reverse shoulder 
arthroplasty wiht a minimum 3 years follow-up (mean 8 
years). 
II. PATIENT AND METHODS 
Study Design 
The current research project refers to a retrospective 
observational study on a consecutive series of patients 
underwent to anatomical and reverse shoulder 
replacement with the prosthetic devices available at the 
Unit of Shoulder and Elbow Surgery of D. Cervesi 
Hospital in Cattolica (Italy) where the same patients were 
enrolled for preoperative clinical and radiographic 
exams.  
Study population and enrollment  
We foresee to enroll 400 subjects with anatomcial and 
reverse total shoulder replacement (Zimmer, Tornier, 
Lima, Biomet) implanted between march 2005 and 
december 2013, to collect preoperative demographic and 
clinical data, technical data of intraoperative phase and 




Anatomical total shoulder arthroplasty assessed in this 
study includes: i) unconstrained monoblock or modular 
humeral components, ii) unstemmed hydrossyapatite 
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coated “corolla” impacted without cement in the humeral 
methaphysis (TESS®), iii). short stem prostheses with a 
prevalent methaphysal grip. Head prostheses available in 
several size, standard or with eccentric offset. Glenoid 
prostheses including: i) polyethylene components with 
keel or pegs, fixed in the cancellous bone with cement; 
the pegged glenoid are also available with a flanged 
uncemented central peg to promote osseointegration, ii) 
standard metal-backed glenoid fixed with screw and 
covered with a polyethylene liner, iii) trabecular 
tantalium-backed glenoid (TMT®) fixed in the bone 
under pressure.  
Reverse 
Reverse prostheses assessed in this study is a 
semiconstrained totally modular device. The glenoid 
component consist of a baseplate (metaglene), provided 
with a large central peg and secured to the native glenoid 
by cortical screws (2 or 4), which may be straight or 
angled, on which is fit  the glenosphere (a rounded metal 
ball approximately two third of sphere) that is attached to 
the baseplate with a screw. The glenosphere can be 
completely medialized or slightly lateralized, to prevent 
scapular neck erosion.  The humeral component consists 
of a proximal cup-shaped portion and a metal stem to be 
press-fitted or cemented in the medullary canal. A 
radiolucent polyethylene insert sits in this cup portion 
and articulates with the glenosphere. As for the 
anatomical implantants, also for reverse prostheses are 
available short stem having a predominantely 
metaphyseal grip. 
Clinical and radiographic evaluation 
Preoperative and postoperative clinical outcomes will be 
evaluated with the Constant-Murley score (CS) 9. The 
CS includes a subjective questionnaire for pain, the 
ability to perform daily living activity (DLA), an 
objective evaluation of active range of motion (ROM) 
and strength. Pain will be scored on a 15 points scale (0 
severe pain, 15 no pain), while DLA will be scored on a 
20 points scale, with lower scores associated with greater 
impairment on DLA. ROM will be measured using a 
standard goniometer between the upper arm and the 
upper part of the thorax. Shoulder strength will be 
assessed using the Lafayette handheld dynamometer 
(Lafayette Instruments, Lafayette, Ind, USA), that has a 
microprocessor with a resolution of 0.4 lb (0.2 kg) in the 
range 0-50 pounds (0-22.6 kg), 0.03% accuracy with two 
calibration points: 0.25 and 50 lbs (0.11 and 22.6 kg). 
Data will be recorded and analyzed using SPSS v.10 
software (SPSS Inc, Chicago, IL, USA). We will assign 1 
point for each 0.5 kg of strength registered. 
Radiographic assessment included standard AP, outlet 
and axillary views. These radiograms were prescribed 
when the patient was discharged from Cervesi Hospital 
to be shown at the first follow-up visit (mean 2 months) 
and then adviced at 6 months, and every years to assess 
implants features. Clinical and radiographic data of last 
follow-up will be compared with those performed 
annually to detect any pathological features of the 
implants. In anatomical prostheses the following 
parameters will be evaluated 10 orientation of the 
humeral component, translation of the humeral 
component, offset of the humeral head, size and height of 
the humeral head, acromio-humeral distance, distribution 
and fixation of the cement, stress shielding and cortical 
resorption, radiolucent lines, subsidence and tilt of 
glenoid and humeral component, glenoid loosening. 
Axillary radiograph is the gold standard to assess 
subluxation of the prosthetic head in sagittal plane that 
can be classified based on direction and severity as: 
Absent: the humeral head is centred in the glenoid cavity 
Slight: < 25% translation of the centre of the head 
component with respect to the glenoid centre 
Moderate: 25% to 50% translation of the centre of the 
prosthetic head with respect to the glenoid centre 
Severe: > 50% translation of the centre of the head 
component with respect to the glenoid centre. 
In patient with reverse arthroplasty the following 
radiographic features will be analyzed: Scapular notching 
classified according to Nerot et al 11, lucent lines 
around humerus, baseplate and screws, pillar spur, 
instability, component disassembly, baseplate 
mobilizazion or migration.  
Inclusion criteria 
Age: 18 years minimum. 
Gender: male and female. 
Informed Consent - patient or patient's legal 
representative has signed a “Patient Informed Consent 
form”. 
TC or MRI to identify concentric osteoarthritis (Samilson 
grade III and IV) or eccentric osteoarthrits with 
irreparable rotator cuff tear 
Exclusion criteria  
Cognitive limitations that precluded a valid consent to be 
included in the study 
Unwilling to be enrolled  
Lack of appropriate patient information 
Lost to the last follow-up  
Statistical analysis 
Data collected will be summarized descriptively. 
Summaries will routinely describe categorical data as 
counts and percentages, and ninety-five percent 
confidence limits will be generally used to assess 
differences between different implant configurations. 
Summaries describing continuous data will be in the 
form of means, medians, standard deviations, minima, 
and maxima, and ninety-five percent confidence intervals 
will be used to contrast differences. Routine summaries 
of implant survival, return to function, etc. (e.g. time to 
event) will generally be described via the Kaplan-Meier 
method and these will generally be accompanied with the 
corresponding crude rates (expressed as percentages). 
Routine summaries of complication data will be in the 
form of frequencies and percentages. Summaries may be 
further generated for strata within the study population, 
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(e.g. males and females, at different cut-points in the 
body mass index continuum, etc.). Patient confidentiality 
will be protected at all times, and patient identifiers will 
not be included in study summaries. 
Risks and adverse events 
As defined by EN ISO 14155-1 and ISO 14155-2. 
Adverse Event: An “adverse event” is defined as any 
untoward medical occurrence in a subject. This definition 
does not imply that there is a relationship between the 
adverse event and the device under investigation. 
Adverse event is synonymous with complication or 
medical event. 
Serious Adverse Event: A “serious adverse event” is 
defined as an adverse event that results in death, is 
lifethreatening, requires inpatient hospitalisation or 
prolongation of existing hospitalisation, results in 
persistent or significant disability/incapacity. 
Adverse Device Effect: An “adverse device effect” is 
defined as “any untoward and unintended response to a 
medical device”. This definition includes any event 
resulting from insufficiencies or inadequacies in the 
instructions for use or the deployment of the device. This 
definition includes any event that is a result of a user 
error. 
Serious Adverse Device Effect: A “serious adverse device 
effect” is defined as “an adverse device effect that has 
resulted in any of the consequences characteristic of a 
serious adverse event or that might have led to any of 
these consequences if suitable action had not been taken 
or intervention had not been made or if circumstances 
had been less opportune”. 
NOTE: The term “severe” refers to the intensity of the 
event and can be used with any event, without regard to 
whether or not it meets the criteria for being classified as 
“serious” or “unanticipated”. For example, a subject can 
have a severe headache, but it is not a serious event. 
Reporting of Adverse Events and Adverse Device 
Effects 
All adverse events which occur during the study will be 
reported and will identify the following: 
- Description of symptoms 
- Date of onset 
- Severity of symptoms: mild, moderate, severe 
- Relation to device: not related, uncertain, probably, 
definitely 
- Treatment 
- Outcome of treatment: resolved, tolerated, pending, 
study withdrawal, device removed/re-operation, death 
- Additional comments 
Ethical considerations 
Patient Information and Informed Consent 
The investigator must explain to each patient the nature 
of this retrospective study, including any risks and 
benefits, its purpose and procedures and expected 
duration of involvement in the study. Patients have full 
rights to withdraw from the study at any time, 
irrespective of their initial consent. 
Subject Confidentiality 
Confidentiality of patient data will be maintained at all 
times. Patient anonymity will be guaranteed and all 
documentation relating to a subject will be kept in a 
secure location. 
Declaration of Helsinki 
This study will be conducted in accordance with the 
relevant articles of the Declaration of Helsinki as adopted 
by the 18th World Medical Assembly in 1964 and as 
revised in Tokyo (1975), Venice (1983), Hong Kong 
(1989), South Africa (1996) and Edinburgh (2000). 
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